BCPEMI
AZN icon

Bain Capital Public Equity Management II’s AstraZeneca AZN Stock Holding History

Bain Capital Public Equity Management II’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,783
Closed -$444K – 44
2020
Q2 		$444K Buy
+2,783
New +$287K 0.03% 41

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bain Capital Public Equity Management II's AZN Position: Q1 2021 in Review

Bain Capital Public Equity Management II sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 157,494 shares — an estimated $15.7M sold.

Bain Capital Public Equity Management II first reported a position in AZN in Q2 2020 and held it in 2 quarters. The position peaked at $23.3M in Q2 2020. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

  • Bain Capital Public Equity Management II reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
  • Bain Capital Public Equity Management II sold 157,494 AstraZeneca shares in Q1 2021, an estimated $15.7M.
  • Bain Capital Public Equity Management II first reported a position in AstraZeneca in Q2 2020 and held it in 2 quarters.
  • Bain Capital Public Equity Management II's AstraZeneca position peaked at $23.3M in Q2 2020.
  • 756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Bain Capital Public Equity Management II's 13F filing for Q1 2021, filed 17 May 2021.